Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain 30B pseudogene 2 (ANKRD30BP2)
- Target
- ANKRD30BP2
- Molecular classification
- Cancer/testis antigen (CTA), Pseudogene, Other
01
Overview
Ankyrin repeat domain 30B pseudogene 2 (ANKRD30BP2), also known as CT85, CTSP-1, cancer/testis antigen 85, and C21orf99, is a member of the cancer/testis antigen family characterized by highly restricted expression in adult testis and aberrant expression in several cancers, most notably prostate cancer. ANKRD30BP2 is a pseudogene that, despite its annotation, has been shown to be aberrantly transcribed and to elicit a humoral immune response in a subset of cancer patients. Antibodies against CTSP-1/ANKRD30BP2 are detected in about 20% of prostate cancer patients and are a favorable prognostic indicator, with a lower risk of biochemical recurrence. As a CTA, ANKRD30BP2 is under investigation as both a biomarker and a potential immunotherapeutic target, although no direct drugs or therapeutics currently act on it. Major challenges include variable tumor expression and the need for combination biomarker approaches due to tumor heterogeneity.
- Other names
- CT85CTSP-1cancer/testis antigen 85C21orf99chromosome 21 open reading frame 99
02
Biological functions
Elicits humoral immune response in cancersExpressed in adult testis and various advanced cancersOther
03
Disease associations
Cancer (especially prostate cancer)Potential role in other solid tumors as a CTA
04
Safety considerations
Potential tumor cell heterogeneity, leading to variable expression and responsiveness to CTA-based therapiesExpression in testis (immune-privileged organ), consideration for on-target/off-tumor effects in immunotherapy
05
Biomarkers
Prognostic biomarker in prostate cancer patients (presence of anti-CTSP-1/ANKRD30BP2 antibodies correlates with better prognosis)General cancer/testis antigen-based biomarker utility
Beyond the preview
Go deeper on Ankyrin repeat domain 30B pseudogene 2 (ANKRD30BP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ankyrin repeat domain 30B pseudogene 2 (ANKRD30BP2).